Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash from Operations: 2021-2022

Historic Cash from Operations for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$1.3 million.

  • Cardiol Therapeutics' Cash from Operations rose 74.40% to -$1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$14.7 million, marking a year-over-year change of. This contributed to the annual value of -$18.3 million for FY2024, which is 1.92% up from last year.
  • According to the latest figures from Q3 2022, Cardiol Therapeutics' Cash from Operations is -$1.3 million, which was up 35.50% from -$2.0 million recorded in Q2 2022.
  • Cardiol Therapeutics' 5-year Cash from Operations high stood at -$1.3 million for Q3 2022, and its period low was -$8.2 million during Q1 2022.
  • Moreover, its 2-year median value for Cash from Operations was -$4.9 million (2021), whereas its average is -$4.3 million.
  • Within the past 5 years, the most significant YoY rise in Cardiol Therapeutics' Cash from Operations was 74.40% (2022), while the steepest drop was 46.90% (2022).
  • Cardiol Therapeutics' Cash from Operations (Quarterly) stood at -$3.2 million in 2021, then surged by 74.40% to -$1.3 million in 2022.
  • Its Cash from Operations stands at -$1.3 million for Q3 2022, versus -$2.0 million for Q2 2022 and -$8.2 million for Q1 2022.